Filing Details

Accession Number:
0001209191-18-017197
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-06 16:08:46
Reporting Period:
2018-03-03
Accepted Time:
2018-03-06 16:08:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818686 Teva Pharmaceutical Industries Ltd TEVA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1726096 Richard Daniell C/O Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva L3 4951033
Exec. Vp, European Commercial No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2018-03-03 2,098 $0.00 2,098 No 4 M Direct
Ordinary Shares Disposition 2018-03-05 990 $19.28 1,108 No 4 F Direct
Ordinary Shares Disposition 2018-03-05 1,108 $19.28 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Share Units Disposition 2018-03-03 2,098 $0.00 2,098 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
6,297 No 4 M Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  3. Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021.